A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Back to home » Top Stories » CROI 2009
CROI 2009 16th Conference on Retroviruses and Opportunistic Infections
Montréal, Canada
February 8-11, 2009

D:A:D Study: Reduce Modifiable Risk Factors to Improve Survival

February 11, 2009

By Tim Horn

Despite the effectiveness of antiretroviral (ARV) therapy, people living with HIV face a higher risk of death than their age-matched HIV-negative peers. However, many risk factors that contribute to an increased risk of death are modifiable—they can often be amended with behavioral changes and proper medical care. During a presentation at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal, Colette Smith, MD, of the University College of London Medical School, showed just how many modifiable risk factors there are. She reported intriguing data from the international D:A:D study.

Non-modifiable risk factors associated with death—characteristics that cannot be changed—include gender and age. Modifiable risk factors associated with HIV include CD4 cell counts and viral load, both of which can be remedied using ARV therapy. Non-HIV modifiable risk factors include smoking, a low body-mass index (low body weight in relation to height), diabetes, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and high blood pressure.

The analysis involved a total of 2,192 deaths reported among 33,347 patients participating in one of 11 cohorts involved in the international D:A:D study. Seventy-four percent of the participants who died were men; 45 percent were white (10 percent were black, and 45 percent were “other”); 43 percent were men who have sex with men; and 18 percent were intravenous drug users. Additionally, 34 percent were current cigaratte smokers and 17 percent were ex-smokers.

About 32 percent of the deaths were AIDS related. Another 14 percent were tied to underlying liver disease; 12 percent to non-AIDS-related cancers, such as skin, lung and head and neck malignancies; 11 percent to cardiovascular disease; and 31 percent to conditions listed as “other” (9 percent of fatalities were “non-natural,” such as suicide, murder and accidents).

Overall, smoking (current vs. never) increased the risk of death by approximately 20 percent. Diabetes increased the risk by 83 percent, HCV by 45 percent and HBV by 29 percent. As for HIV-related modifiable risk factors, having a viral load above 400 copies while on treatment increased the risk of death by 56 percent. Being off HIV treatment, but with a viral loads below 10,000 copies/mL, was associated with a 77 percent increase in the risk of death. Being off treatment with a viral load above 100,000 copies more than tripled the risk of death. And for every 50 CD4 cell drop, the risk of death increased by about 20 percent.

Death due to AIDS was associated with body mass index below 18 (compared with individuals with BMIs between 18 and 26), which quadrupled the risk. Dying of AIDS was also associated with diabetes (a 50 percent increase), a low CD4 count, a detectable viral load (ranging from 84 percent increased risk while on treatment to a quadrupled risk if off treatment) and older age.

Liver-related deaths were tied to high blood pressure , essentially tripling the risk. Diabetes more than doubled the risk, HCV quadrupled the risk, and HBV doubled the risk.  A low CD4 count, a detectable viral load while on treatment (ranging from a 34 percent increase to a more than doubled risk) and older age also contributed to increased rates of liver-related deaths.

Deaths caused by underlying cardiovascular disease were more common among smokers (a 57 percent increase) and those with high blood pressure and diabetes, each of which more than doubled the risk.

Non-AIDS-related cancer deaths were more likely among smokers (a 61 percent increase), low BMI (a quadrupled risk) and a low CD4 count. Interestingly, there appeared to be a trend toward an even higher risk of non-AIDS-related cancers among former smokers compared with current smokers, although Smith did not report on a statistical comparison between these two specific groups of people and did suggest that some individuals may not have quit early enough to avoid particular health issues.

These findings, Smith said, “reiterate the importance of addressing traditional, non-HIV specific risk factors in order to further reduce death rates in HIV-positive populations.” And while there appears to be an association between CD4 counts, viral loads and non-AIDS deaths, Smith bleakly pointed out “there is currently little evidence that modifying these markers will reduce the risk of non-AIDS mortality.” It is important to note, however, that other studies are suggest lower rates of non-AIDS-related health problems among patients starting ARV therapy earlier than is currently recommended and likely followed in the D:A:D study.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       

More from CROI 2009

HIV/AIDS Complications

March 4, 2009
HIV and Women
February 26, 2009
HIV and the Brain: What to Watch Out For
February 25, 2009
HIV and Cancer: Prevalence and Prevention
February 23, 2009
Half of Deaths in People With HIV No Longer From AIDS
February 20, 2009
Testosterone Therapy: Good for Women Too
Lymphoma: Death Rates Still High, but Cancer May Be Predicted
February 19, 2009
Quarter of U.S. Positive Women Not Receiving Annual Pap Smears
February 18, 2009
HDL and Small HDL Particles Predict Cardio Problems in HIV
Scientists Still Seeking Clues to Abacavir Heart Attack Mystery
February 17, 2009
Smoking Cessation: Hispanics, Nicotine Patch Users Do Best
Nerve Damage Is a Common Problem in People With HIV
February 11, 2009
PIs, Abacavir and Cardiovascular Disease: What’s the Risk?
D:A:D Study: Reduce Modifiable Risk Factors to Improve Survival
HIV Itself Is a Major Heart Disease Risk Factor
February 10, 2009
Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIV
February 9, 2009
Diabetes Drug Avandia Helps Reverse Lipoatrophy

HIV Transmission and Prevention

February 27, 2009
Prevention Highlights, Part 1: PrEP
Prevention Highlights, Part 2: Treatment as Prevention
February 13, 2009
Microbicides Make a Comeback
February 9, 2009
HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmission

Starting and Switching Treatment

February 12, 2009
Isentress Shows Long-Term Benefits in Treatment-Experienced Patients
Antidepressants Improve Viral Load Response to Treatment Due to Better Adherence
February 10, 2009
Start HIV Treatment Early—But When?
February 9, 2009
Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Risk

Experimental HIV Drugs

February 20, 2009
Antiretroviral Highlights from CROI
February 10, 2009
IL-2 Fails in Two Large Studies
February 9, 2009
GS 9350 and SPI-452: Emerging Alternatives to Norvir Boosting


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.